Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Tectonic TherapeuticTECX -7.84%14 Piotroski F-Score is 2 as of Aug. 13, 2026, which is 33% below its 10-year median of 3.00. GuruFocus rates TECX with a GF Score™ of 14/100. The stock has 3 warning signs investors should review. Among 1,320 Biotechnology companies, Tectonic Therapeutic ranks worse than 72.95% on this metric.
Warning Sign:
Piotroski F-Score of 2 is low, which usually implies poor business operation.
The zones of discrimination were as such:
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Tectonic Therapeutic has an F-score of 2. It is a bad or low score, which usually implies poor business operation.
The historical rank and industry rank for Tectonic Therapeutic's Piotroski F-Score or its related term are showing as below:
TECX'
s Piotroski F-Score Range Over the Past 10 Years
Min: 2 Med: 3 Max: 4
Current: 2
During the past 5 years, the highest Piotroski F-Score of Tectonic Therapeutic was 4. The lowest was 2. And the median was 3.
The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.
He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.
He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.
What he found was something that exceeded his most optimistic expectations.
Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.
Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).
Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.
Tectonic Therapeutic Piotroski F-Score Related Terms
Tectonic Therapeutic Piotroski F-Score Historical Data
* Premium members only.
The historical data trend for Tectonic Therapeutic's Piotroski F-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TECX vs ZVRA, SPRY, RLMD: Piotroski F-Score Comparison
For the Biotechnology subindustry, Tectonic Therapeutic's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tectonic Therapeutic Piotroski F-Score vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Tectonic Therapeutic's Piotroski F-Score distribution charts can be found below:
* The bar in red indicates where Tectonic Therapeutic's Piotroski F-Score falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.
Profitability
Question 1. Return on Assets (ROA)
Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
Tectonic Therapeutic's current Net Income (TTM) was -85.79.
==> Negative ==> Score 0.
Question 2. Cash Flow Return on Assets (CFROA)
Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
Tectonic Therapeutic's current Cash Flow from Operations (TTM) was -72.14.
==> Negative ==> Score 0.
Question 3. Change in Return on Assets
Compare this year's return on assets (1) to last year's return on assets.
Tectonic Therapeutic's return on assets of this year was -0.29049517. Tectonic Therapeutic's return on assets of last year was -0.34026095.
==> This year is higher. ==> Score 1.
Question 4. Quality of Earnings (Accrual)
Compare Cash flow return on assets (2) to return on assets (1)
Tectonic Therapeutic's gearing of this year was 0.01070265. Tectonic Therapeutic's gearing of last year was 0.00082617.
==> Last year is lower than this year ==> Score 0.
Question 6. Change in Working Capital (Liquidity)
Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.
Score 1 if this year's current ratio is higher, 0 if it's lower
Tectonic Therapeutic's current ratio of this year was 22.28739512. Tectonic Therapeutic's current ratio of last year was 25.60056333.
==> Last year's current ratio is higher ==> Score 0.
Question 7. Change in Shares in Issue
Compare the number of shares in issue this year, to the number in issue last year.
Score 0 if there is larger number of shares in issue this year, 1 otherwise.
Tectonic Therapeutic's number of shares in issue this year was 18.964. Tectonic Therapeutic's number of shares in issue last year was 18.68.
==> There is larger number of shares in issue this year. ==> Score 0.
Efficiency
Question 8. Change in Gross Margin
Compare this year's gross margin (Gross Profit divided by sales) to last year's.
Score 1 if this year's gross margin is higher, 0 if it's lower.
Tectonic Therapeutic's gross margin of this year was . Tectonic Therapeutic's gross margin of last year was .
==> Last year's gross margin is higher ==> Score 0.
Question 9. Change in asset turnover
Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.
Score 1 if this year's asset turnover ratio is higher, 0 if it's lower
Tectonic Therapeutic's asset turnover of this year was 0. Tectonic Therapeutic's asset turnover of last year was 0.
==> Last year's asset turnover is higher ==> Score 0.
Evaluation
Piotroski F-Score
=
Que. 1
+
Que. 2
+
Que. 3
+
Que. 4
+
Que. 5
+
Que. 6
+
Que. 7
+
Que. 8
+
Que. 9
=
0
+
0
+
1
+
1
+
0
+
0
+
0
+
0
+
0
=
2
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Tectonic Therapeutic has an F-score of 2. It is a bad or low score, which usually implies poor business operation.
Tectonic Therapeutic (TECX) has a Piotroski F-Score of 2 as of Aug. 13, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Tectonic Therapeutic and its competitors. This is 33% below median its historical median of 3.00. Over the past decade, Tectonic Therapeutic's Piotroski F-Score has ranged from 2.00 to 4.00. According to the industry distribution chart, Tectonic Therapeutic ranks #963 out of 1320 companies in the Biotechnology industry, placing it in the top 73%.
Is Tectonic Therapeutic's Piotroski F-Score too high?
Tectonic Therapeutic's current Piotroski F-Score of 2 is 33% below median its 10-year median of 3.00. Over the past 10 years, this metric has ranged from a low of 2.00 to a high of 4.00. The Biotechnology industry median Piotroski F-Score is 3.00. Tectonic Therapeutic's value of 2 is 33.3% below this industry median. Based on the distribution chart, Tectonic Therapeutic ranks #963 out of 1320 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Tectonic Therapeutic has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Tectonic Therapeutic's Piotroski F-Score compare to ZVRA and SPRY?
According to the Biotechnology industry distribution chart, Tectonic Therapeutic ranks #963 out of 1320 companies for Piotroski F-Score. This places Tectonic Therapeutic in the lower half of its industry. The industry median Piotroski F-Score is 3.00. Tectonic Therapeutic's value of 2 is 33.3% below this benchmark. Historically, Tectonic Therapeutic's own Piotroski F-Score has ranged from 2.00 to 4.00 over the past decade. While the company's 10-year median is 3.00 vs. the industry median of 3.00, Tectonic Therapeutic has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Biotechnology company?
The median Piotroski F-Score among Biotechnology companies is 3.00, based on 1,320 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tectonic Therapeutic's current Piotroski F-Score of 2 is 33.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Tectonic Therapeutic and its competitors. For the Biotechnology industry, the median Piotroski F-Score is 3.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tectonic Therapeutic's current Piotroski F-Score is 2, which is 33% below median its own 10-year median of 3.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tectonic Therapeutic stock overvalued right now?
Tectonic Therapeutic (TECX) has a current Piotroski F-Score of 2. The current Piotroski F-Score is 2, which is 33% below median its 10-year median of 3.00 and 33.3% below the Biotechnology industry median of 3.00. Tectonic Therapeutic's overall GF Score™ is 14/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Tectonic Therapeutic (TECX), the current Piotroski F-Score is 2 as of Aug. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. The company focuses on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.
14GF Score
Get the complete analysis for TECX
Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TECX has been successfully added to your 
